440 related articles for article (PubMed ID: 9932729)
21. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
22. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
[TBL] [Abstract][Full Text] [Related]
23. Ex-vivo and in-vivo antithrombotic effect of triflavin, an RGD-containing peptide.
Sheu JR; Huang TF
J Pharm Pharmacol; 1994 Jan; 46(1):58-62. PubMed ID: 8201528
[TBL] [Abstract][Full Text] [Related]
24. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of hippocampal LTP by ginkgolide B is mediated by its blocking action on PAF rather than glycine receptors.
Kondratskaya EL; Pankratov YV; Lalo UV; Chatterjee SS; Krishtal OA
Neurochem Int; 2004 Feb; 44(3):171-7. PubMed ID: 14568560
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.
Schattner M; Parini A; Fouque F; Vargaftig BB; Touqui L
Br J Pharmacol; 1989 Apr; 96(4):759-66. PubMed ID: 2787179
[TBL] [Abstract][Full Text] [Related]
27. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage.
Vercellotti GM; Yin HQ; Gustafson KS; Nelson RD; Jacob HS
Blood; 1988 Apr; 71(4):1100-7. PubMed ID: 2451547
[TBL] [Abstract][Full Text] [Related]
28. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
29. Bakkenolide G, a natural PAF-receptor antagonist.
Liao CH; Ko FN; Wu TS; Teng CM
J Pharm Pharmacol; 1997 Dec; 49(12):1248-53. PubMed ID: 9466352
[TBL] [Abstract][Full Text] [Related]
30. Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.
Pons F; Rossi AG; Norman KE; Williams TJ; Nourshargh S
Br J Pharmacol; 1993 May; 109(1):234-42. PubMed ID: 8495241
[TBL] [Abstract][Full Text] [Related]
31. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
Castro-Faria-Neto HC; Bozza PT; Cruz HN; Silva CL; Violante FA; Barbosa-Filho JM; Thomas G; Martins MA; Tibiriçá EV; Noel F
Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
[TBL] [Abstract][Full Text] [Related]
32. Effects of antiplatelet agents on platelet aggregation induced by platelet--activating factor (PAF) in human whole blood.
Chan WP; Levy JV
Prostaglandins; 1991 Oct; 42(4):337-42. PubMed ID: 1665568
[TBL] [Abstract][Full Text] [Related]
33. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of platelet-activating factor- and zymosan-activated serum-induced chemotaxis of human neutrophils by nedocromil sodium, BN 52021 and sodium cromoglycate.
Bruijnzeel PL; Warringa RA; Kok PT
Br J Pharmacol; 1989 Aug; 97(4):1251-7. PubMed ID: 2551444
[TBL] [Abstract][Full Text] [Related]
35. Platelet-activating factor as an intercellular signal in neutrophil-dependent platelet activation.
Zhou W; Javors MA; Olson MS
J Immunol; 1992 Sep; 149(5):1763-9. PubMed ID: 1506691
[TBL] [Abstract][Full Text] [Related]
36. An antagonistic activity of etizolam on platelet-activating factor (PAF). In vitro effects on platelet aggregation and PAF receptor binding.
Mikashima H; Takehara S; Muramoto Y; Khomaru T; Terasawa M; Tahara T; Maruyama Y
Jpn J Pharmacol; 1987 Aug; 44(4):387-91. PubMed ID: 2890779
[TBL] [Abstract][Full Text] [Related]
37. Elvax as a slow-release delivery agent for a platelet-activating factor receptor agonist and antagonist.
Bix GJ; Clark GD
J Neurosci Methods; 1997 Nov; 77(1):67-74. PubMed ID: 9402559
[TBL] [Abstract][Full Text] [Related]
38. A potent antiplatelet peptide, triflavin, from Trimeresurus flavoviridis snake venom.
Huang TF; Sheu JR; Teng CM
Biochem J; 1991 Jul; 277 ( Pt 2)(Pt 2):351-7. PubMed ID: 1859363
[TBL] [Abstract][Full Text] [Related]
39. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation.
Sheu JR; Lin CH; Peng HC; Teng CM; Huang TF
Jpn J Cancer Res; 1993 Oct; 84(10):1062-71. PubMed ID: 8226281
[TBL] [Abstract][Full Text] [Related]
40. Histamine potentiates human platelet aggregation induced by platelet-activating factor.
Sipka S; Koltai M; Braquet P; Szegedi G
Int Arch Allergy Immunol; 1992; 97(1):89-92. PubMed ID: 1582704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
